Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (25)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fabrizi, F.
Right arrow Articles by Locatelli, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fabrizi, F.
Right arrow Articles by Locatelli, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (1994) 9: 780-784
© 1994 European Renal Association-European Dialysis and Transplant Association

research-article

Antibodies to hepatitis C virus (HCV) in chronic renal failure (CRF) patients on conservative therapy: prevalence, risk factors and relationship to liver disease

F. Fabrizi1,, D. Marcelli, G. Bacchini1, I. Guarnori2, G. Erba2 and F. Locatelli1

1Nephrology Department, Hospital Lecco Lecco, Italy 2Transfusion Centre, Hospital Lecco Lecco, Italy

Correspondence and offprint requests to: Correspondence and offprint requests to: Dr Fabrizio Fabrizi, Nephrology Division, Hospital of Lecco, via Ghislanzoni 22, 22053 Lecco, Italy

There are no data regarding HCV prevalence in CRF patients not requiring dialysis. In order to assess prevalence and risk factors for HCV infection in CRF patients on conservative therapy we tested, by second-generation assays such as Ortho 2 and 4-RIBA, 221 predialysis CRF patients attending our Department. Forty-four (20%) patients were anti-HCV positive. Anti-HCV positivity was related to blood transfusion requirement, past or current elevations of transaminase levels and, to a lesser degree, CRF duration. The prevalence of anti-HCV positivity among CRF patients who were never transfused was about 10 times higher than that of blood donors. Our data show that predialysis CRF patients should be considered a specific risk group for HCV infection; blood transfusion history and duration of CRF are risk factors for acquisition of HCV infection; HCV infec tion may play a role in the development of liver disease in this clinical setting.

Keywords: hepatitis C virus; anti-HCV antibodies; renal failure


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.